Connect with us

Technology

eClinical Solutions Market to Grow by USD 12.77 Billion (2024-2028), Rising Drug Clinical Trials Drive Revenue, Report Highlights AI Impact on Trends – Technavio

Published

2 years ago

on

NEW YORK, Dec. 5, 2024 /PRNewswire/ — Report on how AI is redefining market landscape – The global eclinical solutions market  size is estimated to grow by USD 12.77 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  15.26%  during the forecast period. Rise in clinical trials for drugs is driving market growth, with a trend towards increasing outsourcing of clinical trial processes. However, rising cost of clinical trials  poses a challenge. Key market players include Advarra Inc., Aixial, Anju Software Inc., ArisGlobal LLC, Castor Research Inc., Dassault Systemes SE, DATATRAK International Inc., eClinical Solutions LLC., eClinicalWorks LLC, eResearchTechnology GmbH, International Business Machines Corp., MedNet, Medrio Inc., OpenClinica LLC, Oracle Corp., Parexel International Corp., Saama Technologies Inc., Signant Health, Veeva Systems Inc., and YPrime LLC.

AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

End-user (Pharmaceutical and biotechnology companies, Contract research organizations, Consulting service companies, Medical device manufacturers, and Others), Deployment (Cloud-based and On-premises), and Geography (North America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

Advarra Inc., Aixial, Anju Software Inc., ArisGlobal LLC, Castor Research Inc., Dassault Systemes SE, DATATRAK International Inc., eClinical Solutions LLC., eClinicalWorks LLC, eResearchTechnology GmbH, International Business Machines Corp., MedNet, Medrio Inc., OpenClinica LLC, Oracle Corp., Parexel International Corp., Saama Technologies Inc., Signant Health, Veeva Systems Inc., and YPrime LLC

Key Market Trends Fueling Growth

The eClinical solutions market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development for various chronic diseases such as cancer, cardiovascular conditions, and infectious diseases. The enormous data generated during these trials requires advanced software solutions for clinical data management (CDM) and clinical trial management systems (CTMS). EClinical solutions like Veeva Systems and PAREXE are gaining popularity due to their benefits of real-time access, error reduction, and cost efficiency. The rising number of clinical trials and observational studies, coupled with research funding, is driving the adoption of eClinical solutions. However, the lack of awareness and high costs are challenges for smaller enterprises and underdeveloped markets. The digitization of healthcare through the Internet of Things and information technologies is also influencing the market. Firms like TRIO and CROs are focusing on clinical randomization, supply management, and site performance to improve drug development and retention. Healthcare engineering, clinical researchers, and healthcare providers are also integrating eClinical solutions into their clinical trial processes, leading to growth opportunities for eClinical solution providers. The market is characterized by a firm concentration ratio, with major players like Veeva Systems and PAREXE dominating. The market also includes academic universities, hospitals, research centers, and process outsourcing firms. The development of medical devices and IT infrastructure, such as EDC, CDMS, and web-hosted or cloud-based clinical trials, are also contributing to the market’s growth. Consultancy services and licenced enterprise solutions are also available to support the market. 

The eClinical Solutions Market has witnessed significant changes in the past decade, with a shift towards outsourcing drug discovery processes to subcontract laboratories. This trend is driven by increased R&D investments and the focus on core competencies in manufacturing and marketing. Since 2011, the number of subcontract laboratories has grown rapidly, and this trend is expected to continue. The industry has transformed from a vertical reporting model with in-house clinical study teams to a matrix model involving both external and internal resources. Gradually, the bulk of the work has moved to Contract Research Organizations (CROs). This outsourcing trend enables companies to reduce costs, improve efficiency, and focus on their core competencies. 

Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!

Market Challenges

•         The eClinical solutions market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development for unmet medical needs in healthcare. The rising number of clinical trials for chronic diseases such as cancer, cardiovascular conditions, and infectious diseases, requires enormous data management. EClinical solutions like Veeva Systems and TRIO are addressing these challenges by providing software solutions for clinical data management (CDM), clinical trial management systems (CTMS), and clinical randomization. However, there are challenges such as high costs, lack of awareness, and integration issues with various systems like CDM, clinical research organizations (CROs), academic universities, hospitals, and research centers. The digitization of healthcare through the Internet of Things and information technologies is driving the need for data standardization and real-time access to clinical trial data. Smaller enterprises and developing markets face challenges in technology adoption due to the high costs and lack of internet connectivity. However, the benefits of eClinical solutions like cost efficiency, site performance, and error reduction make them an attractive option for clinical researchers and healthcare providers. Firms with a high firm concentration ratio, such as pharmaceutical companies and medical device manufacturers, are investing in eClinical solutions for clinical trial processes, supply management, and protocol matrices. Consultancy services like PAREXE are providing expertise in clinical trial processes and regulatory compliance to help firms navigate the complex clinical trial landscape. The growth opportunities in this market are vast, with a particular focus on clinical trial processes, drug development, and clinical research.

•         Clinical trials are a crucial part of bringing new drugs to market, but their cost has become a significant concern. Factors contributing to this increase include the complex and lengthy process of patient enrolment and retention. According to recent studies, the cost per patient in clinical trials rose by over 150% in the US between 2010 and 2015, and by 85-90% in the UK during the same period. These figures underscore the need for effective clinical trial management solutions to streamline processes, improve patient engagement, and reduce costs.

Insights into how AI is reshaping industries and driving growth- Download a Sample Report

Segment Overview 

This eclinical solutions market report extensively covers market segmentation by

End-user 1.1 Pharmaceutical and biotechnology companies1.2 Contract research organizations1.3 Consulting service companies1.4 Medical device manufacturers1.5 OthersDeployment 2.1 Cloud-based2.2 On-premisesGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Pharmaceutical and biotechnology companies-  Clinical trials are a crucial part of the drug development process for pharmaceutical and biotechnology companies. The success of these trials is essential for bringing new treatments to market. However, clinical trials are lengthy and expensive, and failures can result in significant financial and time losses. Regulatory scrutiny and the need for high-quality data have led to the increased adoption of eClinical solutions, such as Clinical Trial Management Systems (CTMS), among these companies. Mundipharma Research, a pharmaceutical research and development company, and GlaxoSmithKline, one of the largest pharmaceutical companies, are among those that have implemented eClinical solutions to enhance the efficiency and control of their clinical trials. These web-based systems provide real-time access to trial information, faster decision-making, decreased trial costs, and increased employee productivity and job satisfaction. With the rise in the number of clinical trials due to the increasing number of diseases and advanced treatments in development, the demand for eClinical solutions is on the rise. These solutions help companies manage the complexities of clinical trials, ensuring regulatory compliance, data accuracy, and operational efficiency. The market for eClinical solutions is expected to grow significantly during the forecast period as more companies recognize the benefits of these technologies in bringing new treatments to market.

Download complimentary Sample Report to gain insights into AI’s impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 – 2022) 

Research Analysis

The eClinical solutions market is experiencing significant growth due to the enormous data generated from clinical trials in healthcare. The rising number of clinical trials and emphasis on eClinical solutions for research is driving the market forward. Software solutions like ClinicalTrials.gov and TRIO are increasingly being adopted by cancer centers and healthcare institutions to streamline clinical research. Observational studies are also benefiting from eClinical solutions, allowing for more efficient data collection and analysis. The Internet of Things (IoT) is playing a major role in the technology adoption, enabling real-time patient monitoring and data collection. Research funding agencies are recognizing the value of eClinical solutions and are encouraging their use in clinical research. Minor trials are also benefiting from these solutions, making clinical research more accessible and efficient for all.

Market Research Overview

The eClinical Solutions Market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development in healthcare. With an enormous amount of data being generated in clinical research, there is a rising need for software solutions to manage this data effectively. EClinical solutions, such as TRIO and PAREXE, are gaining popularity in cancer centers, clinical research organizations (CROs), pharmaceutical companies, and academic universities. The digitization of healthcare and the Internet of Things are driving the adoption of eClinical solutions, which offer benefits like real-time access to clinical trial data, improved clinical trial processes, and increased cost efficiency. However, the lack of awareness and high costs associated with these solutions pose challenges for smaller enterprises and underdeveloped markets. The market is characterized by a firm concentration ratio, with major players like Veeva Systems dominating. Growth opportunities exist in developing and underdeveloped markets, where there is a high demand for clinical trials in chronic diseases such as diabetes, cancer, cardiovascular conditions, and infectious diseases. EClinical solutions include Clinical Trial Management Systems (CTMS), Clinical Data Management Systems (CDMS), Electronic Data Capture (EDC), and Clinical Randomization Systems. These solutions help manage clinical trial processes, supply management, site performance, and retention. The benefits of eClinical solutions include error reduction, data standardization, and improved communication between clinical researchers, healthcare providers, and academic universities. However, the adoption of these solutions requires IT infrastructure and internet connectivity, which can be a challenge in some markets. Medical devices and consultancy services are also integral to the eClinical Solutions Market, offering additional benefits like protocol matrices, drug development, and clinical research. Overall, the market is expected to continue growing as unmet medical needs and the importance of clinical trials in drug development increase.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

End-userPharmaceutical And Biotechnology CompaniesContract Research OrganizationsConsulting Service CompaniesMedical Device ManufacturersOthersDeploymentCloud-basedOn-premisesGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/eclinical-solutions-market-to-grow-by-usd-12-77-billion-2024-2028-rising-drug-clinical-trials-drive-revenue-report-highlights-ai-impact-on-trends—technavio-302322403.html

SOURCE Technavio

Related Topics:
Continue Reading

Technology

Toku launches Makimoto Flows, a visual builder for speech AI pipelines, taking its open-source initiative beyond transcription

Published

24 minutes ago

on

October 21, 2026

By

Developers can chain transcription, summarisation and call tagging on one canvas, test each step and export the pipeline as code, with every step processed in Singapore

SINGAPORE, Oct. 21, 2026 /PRNewswire/ — Toku Ltd. (SGX: TKU), a Singapore-headquartered AI-powered customer experience (CX) platform, has launched Makimoto Flows (“Flows”), a visual builder within its open-source conversational AI initiative where developers assemble speech AI pipelines block by block and test each stage on a recorded call. Flows is now live at makimoto.ai.

On the Flows canvas, developers connect blocks to build a speech AI pipeline and test each step individually. The Transcribe block converts audio into text using Kawa, the Summarise block generates a topic and short summary from the transcript, and the Tags block classifies each call across seven categories, including customer sentiment. Developers can see how audio moves from transcription to analysis, and control how each stage connects and runs. Every block runs in Singapore, so audio, transcripts and the resulting analysis stay in-country.

The Chained Analysis starter template puts these blocks together in one click, and developers can adjust any block and rerun it to compare results. Each block maps to a Makimoto API endpoint, and any flow can be exported as ready-to-run Python code, so developers can take the same capabilities into their own code for applications such as call recaps and call triage.

“Developers should have control over how their voice AI works, from the models they use to the way each stage connects. That is the principle behind Makimoto. Flows puts the orchestration layer in front of them: they can build a pipeline, run a recorded call through it and see what each step produces before anything reaches their customers. Models will keep changing. The ability to compose them, and to know where they run, is what lasts,” said Thomas Laboulle, Founder and CEO at Toku.

Flows builds on the composable architecture Toku set out when it introduced Makimoto in April 2026, and takes the initiative beyond transcription. Kawa, released on schedule on 1 July 2026, established the transcription layer through a Singapore-hosted API; summarisation and tagging endpoints followed in September; Flows now lets developers compose them visually. Next, Makimoto plans to add audio preparation blocks, starting with noise filtering, giving developers more control over how recordings are processed before transcription.

By pairing open-source development with enterprise-grade deployment, Makimoto complements Toku’s existing customer experience platform and supports long-term innovation opportunities across the Group’s AI roadmap.

Developers can create a free account at makimoto.ai, open the Chained Analysis template and run a sample recording, or one of their own call recordings, through it; each account includes 1,000 free minutes. Feedback reaches the Makimoto team directly from the portal.

About Toku

Headquartered in Singapore, Toku Ltd. (SGX Catalist: TKU) is a cloud-native, AI-powered customer experience platform purpose-built for enterprises operating in complex, multi-market environments. With deep roots in the APAC region and an expanding global footprint, Toku’s modular 360° CX Platform orchestrates customer interactions across voice, chat, email and digital channels while managing regulatory, linguistic and infrastructure complexity at scale.

Built on end-to-end ownership of its technology stack, from carrier-grade connectivity to AI applications, Toku delivers enterprise-grade security, reliability and deployment flexibility in commercial cloud, private data centres and hybrid environments. Its AI capabilities include transcription, summarisation, sentiment analysis, conversation analytics and governed virtual agents, designed to integrate seamlessly with enterprise systems and customer data.

Trusted by leading enterprises and public-sector organisations, Toku helps organisations streamline operations, scale customer engagement and deliver consistent experiences in fragmented markets worldwide.

For more information about Toku, visit toku.co.

About Makimoto

Makimoto is Toku’s open-source initiative, operated through Makimoto Technology Pte Ltd, a wholly owned subsidiary of the Toku Group, dedicated to building composable conversational AI infrastructure for Asia-Pacific. Its releases include Makimoto Kawa, a Singapore-hosted transcription API; summarisation and tagging endpoints; and Makimoto Flows, a visual builder for composing speech AI pipelines. For more information about Makimoto, visit makimoto.ai.

Forward-Looking Statements

This press release contains forward-looking statements regarding Toku’s expansion plans, business strategy and planned product releases. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Toku undertakes no obligation to update these statements to reflect subsequent events or circumstances.

Sponsor’s Statement

Toku Ltd. (the “Company”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “Exchange”) on 22 January 2026. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). This press release has been reviewed by the Sponsor. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Relations Contact:
investor.relations@toku.co

Developers and Partners:
contact@makimoto.ai  

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/toku-launches-makimoto-flows-a-visual-builder-for-speech-ai-pipelines-taking-its-open-source-initiative-beyond-transcription-302914906.html

SOURCE Toku Ltd.

Continue Reading

Technology

Conscious Spark LLC Launches Alphimiya® Neuro-Recalibration Framework Designed to Resolve C-Suite Revenue Plateaus

Published

24 minutes ago

on

October 21, 2026

By

New research-backed neuro-recalibration framework targets the autonomic nervous system’s threat response to managing high financial amounts, offering enterprise leaders a biological pathway to scaling.

ANTALYA, Turkey and ALBUQUERQUE, N.M., Oct. 21, 2026 /PRNewswire/ — Conscious Spark LLC, a research and advisory firm specializing in applied neuroscience for executive leadership, today announced the official launch of Alphimiya®, a proprietary C-suite neuro-recalibration framework designed to resolve corporate revenue plateaus by upgrading the biological capacity of enterprise decision-makers.

Developed to address the root causes of stalled enterprise growth, the Alphimiya® framework targets the human autonomic nervous system’s subconscious threat response to managing high financial amounts. When commercial leaders and CEOs attempt to scale past historical capital thresholds without recalibrating their stress response, the body’s natural survival mechanism triggers decision fatigue, strategic risk aversion, and systemic self-sabotage. Alphimiya® recalibrates this biological safety brake, enabling executive teams to hold, absorb, and scale larger financial volumes without physiological or operational friction.

“A corporate revenue plateau is rarely an operational or marketing failure; it is a biological safety brake embedded within executive leadership,” stated Dr. Ahmed Al-Nashi, Founder of Conscious Spark LLC. “When managing high financial amounts triggers an underlying physical stress response, the enterprise subconsciously contracts to remain in its perceived safe zone. Alphimiya® removes that biological friction, allowing C-level leaders to multiply revenue with calm, biological authority.”

The Alphimiya® framework restructures executive performance across three core operational pillars:

Sovereign Enterprise Scaling: Expands the nervous system’s tolerance for high-stakes capital, allowing leadership teams to scale revenue without experiencing executive burnout.

High-Value Deal Execution: Regulates autonomic stress responses during multi-million-dollar negotiations and volatile market entries, eliminating hesitation under pressure.

Restored Strategic Clarity: Removes chronic decision fatigue across C-suite teams, restoring mental focus and strategic presence inside and outside the boardroom.

By recalibrating the autonomic nervous system’s response to high capital exposure, Alphimiya® removes the subconscious biological brakes that lock corporate revenue at a standstill. Senior C-level executives and enterprise leadership teams seeking to evaluate their organization’s biological capacity can access the official executive briefing, case studies, and framework assessment directly at https://alphimiya.co/.

About Conscious Spark LLC

Conscious Spark LLC is a U.S.-registered firm specializing in executive education, training, and strategic performance consulting. Pioneering applied neuroscience for C-level leaders, founders, and commercial decision-makers, the firm utilizes its proprietary Alphimiya® methodology to enable leadership teams to recalibrate biological stress responses, resolve revenue ceilings, and build scalable corporations.

Media Relations Team
Conscious Spark LLC
Email: hello@consciousspark.online 
Website: https://alphimiya.co/

View original content to download multimedia:https://www.prnewswire.com/news-releases/conscious-spark-llc-launches-alphimiya-neuro-recalibration-framework-designed-to-resolve-c-suite-revenue-plateaus-302901454.html

SOURCE Conscious Spark LLC

Continue Reading

Technology

Daffodil Software Brings Multilingual Conversational AI to Aadhaar’s Udai Mascot

Published

24 minutes ago

on

October 21, 2026

By

GURUGRAM, India, Oct. 21, 2026 /PRNewswire/ — Daffodil Software showcased an AI-powered conversational experience featuring UIDAI’s Udai mascot at Aadhaar Samvaad 2026. Developed by Daffodil Software, the assistant is designed to help users access Aadhaar-related information through natural conversation, using official UIDAI as its reference knowledge base.

Daffodil Software has developed Udai, an AI-powered virtual mascot that helps users get clear, reliable answers about Aadhaar simply by talking to it. The assistant was showcased at Aadhaar Samvaad 2026, held in Kolkata on 29 September, coinciding with the 17th Aadhaar Day, where visitors watched it listen, respond, and gesture in real time in their own language.

For most people, questions about Aadhaar come up in daily life, and they usually need answers fast. Which documents do I need for an address change? How much does an update cost? How do I link Aadhaar to my bank account or mobile number? The answers exist, but finding them usually means working through long help pages and documents.

 Udai is designed to answer exactly these questions in a natural conversation, without anyone having to search through long help pages.

A conversation in the user’s own language

Udai speaks and understands 11 languages: Hindi, Tamil, Bengali, Telugu, Kannada, Malayalam, Marathi, Gujarati, Punjabi, Odia, and English. A user simply asks a question. Udai listens, works out the answer, and replies in the same language, with natural speech, matching lip movements and expressive hand gestures.

What sets Udai apart is how it is built. AI avatars rely on expensive, specialised graphics hardware to bring a face to life. Udai takes a simpler route. The character is created from pre-filmed footage, and its lip movements are matched to its speech in real time using lightweight processing that runs in a web browser.

The result is a smooth experience at 24 frames per second on ordinary servers, at a fraction of the usual cost per user. For a programme that serves hundreds of millions of people, that efficiency is what turns a nationwide rollout from an ambition into a practical plan.

“Our focus with Udai was to make Aadhaar-related information easier to access through natural conversation. Combining multilingual voice interaction with official reference content allowed our team to build an experience that is practical, approachable, and useful to users,” said Yogesh Agarwal, Founder and CEO, Daffodil Software.

Answers drawn only from official sources

The assistant uses official UIDAI material as its reference knowledge base: frequently asked questions, provisions of the Aadhaar Act, and government policy documents on Aadhaar services. It covers the topics users ask about most:

Enrolment and registrationAddress and demographic updatesFees, required documents and eligibilityeKYC and Virtual IDLinking Aadhaar with bank accounts, PAN and mobile numbersmAadhaar servicesGrievance redressal

Users don’t need to phrase their questions in any particular way. Udai understands everyday language, whether a question is spoken in English, Hindi, or asked in a mix of both, and finds the most relevant official information to answer it.

Built to be accurate, respectful, and secure

When a public service speaks directly to users, trust matters as much as convenience. Udai is protected by three layers of safeguards.

Accuracy first. Udai answers only from its verified knowledge base. Responses are grounded in a curated knowledge base of official UIDAI material. If a question falls outside Aadhaar, it guides the user back rather than offering an answer it cannot stand behind.

Respectful conversations. A screening layer catches abusive or offensive language in English, Hindi, and Hinglish before it reaches the assistant. Screening is designed to identify abusive language while supporting legitimate queries

Protection against misuse. Udai cannot be talked into abandoning its role, pretending to be someone else, revealing its internal setup, or answering beyond its approved scope. These checks work almost instantly, so users experience no delay.

What comes next?

Udai is planned to roll out in two phases.

In the first phase, the mascot will be placed in Aadhaar Centres. Visitors will be able to check information and understand processes on their own, such as which documents they need for an address change. This frees centre staff to focus on their core work instead of answering the same questions again and again.

In the second phase, Udai will come to the Aadhaar website and mobile app, taking the place of the current text-based chatbot, which was also built by Daffodil.

About Daffodil Software

Daffodil Software is a software engineering and AI solutions company serving businesses across industries. Its services span software consulting, product engineering, UI/UX design, AI/ML development, quality assurance, cloud and DevOps, and maintenance. The company serves sectors including healthcare, fintech, banking, technology, and digital commerce. Its client portfolio includes organizations such as the Reserve Bank of India, Mount Sinai Hospital, Maruti, Samsung, Pramerica Insurance, and Dangote Group. Daffodil Software has also been featured in industry research and recognition by Gartner, Everest Group, Zinnov, and Frost & Sullivan. For more information, visit https://www.daffodilsw.com

Media contact

Kunwar Pal Singh
media-relations@daffodilsw.com

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/daffodil-software-brings-multilingual-conversational-ai-to-aadhaars-udai-mascot-302914965.html

Continue Reading

Trending